| Alphonse MP et al. Inositol-Triphosphate 3-Kinase C Médiates Inflammasome Activation and Treatment Response in Kawasaki Disease. J Immunol 25 nov 2016 | Lire le résumé |
| Manlhiot C, Mueller B, O’Shea S, Majeed H, Bernknopf B, Labelle M, et al. Environmental epidemiology of Kawasaki disease: Linking disease etiology, pathogenesis and global distribution. Kuo H-C, editor. PLOS ONE. 2018 Feb 7 | Lire le résumé |
| Chen KYH, Messina N, Germano S, Bonnici R, Freyne B, Cheung M, et al. Innate immune responses following Kawasaki disease and toxic shock syndrome. Proost P, editor. PLOS ONE. 2018 Feb 15. | Lire le résumé |
| Chbeir D, Gaschignard J, Bonnefoy R, Beyler C, Melki I, Faye A, et al. Kawasaki disease: abnormal initial echocardiogram is associated with resistance to IV Ig and development of coronary artery lesions. Pediatric Rheumatology [Internet]. 2018 Dec [cited 2018 Oct 24];16(1). | Lire le résumé |
| Li Y, Li Y, Zheng Q, Zou L, Wu J, Guo L, Teng L, et al. Kawasaki disease shock syndrome: clinical characteristics and possible use of IL-6, IL-10 and IFN-γ as biomarkers for early recognition. Pediatric Rheumatology [Internet]. 2019 Dec [cited 2019 Feb 7];17(1). Available from: https://ped-rheum.biomedcentral.com/articles/10.1186/s12969-018-0303-4 | Lire le résumé |
| Hamada H, Suzuki H, Onouchi Y, Ebata R, Terai M, Fuse S, et al. Efficacy of primary treatment with immunoglobulin plus ciclosporin for prevention of coronary artery abnormalities in patients with Kawasaki disease predicted to be at increased risk of non-response to intravenous immunoglobulin (KAICA): a randomised controlled, open-label, blinded-endpoints, phase 3 trial. The Lancet. mars 2019;393(10176):1128‑37 | Lire le résumé |
| Feldstein LR, Rose EB, Horwitz SM, Collins JP, Newhams MM, Son MBF, et al. Multisystem Inflammatory Syndrome in U.S. Children and Adolescents. N Engl J Med. 23 juill 2020;383(4):334‑46 | Lire le résumé |
